Bill's Feed
Dec 18, 2012

First funerals for Newtown victims as U.S. schools confront tragedy

, Dec 17 (Reuters) – One boy was
buried in his hero’s football jersey in a small white coffin.
Balloons and a teddy bear welcomed mourners to the funeral of
his first grade schoolmate.

The two funerals on Monday ushered in what will be a week of
memorial services and burials for the 20 children and six adults
massacred at Sandy Hook Elementary School in Newtown,
Connecticut.

Dec 18, 2012

Funerals begin in Newtown as schools confront tragedy

FAIRFIELD/NEWTOWN, Connecticut (Reuters) – One boy was buried in his hero’s football jersey in a small white coffin. Balloons and a teddy bear welcomed mourners to the funeral of his first grade schoolmate.

The two funerals on Monday ushered in what will be a week of memorial services and burials for the 20 children and six adults massacred at Sandy Hook Elementary School in Newtown, Connecticut.

Dec 17, 2012

Funerals begin for Newtown victims as schools confront tragedy

FAIRFIELD/NEWTOWN, Connecticut (Reuters) – One boy was buried in his hero’s football jersey in a small white coffin. Balloons and a teddy bear welcomed mourners to the funeral of his first grade schoolmate.

The two funerals on Monday ushered in what will be a week of memorial services and burials for the 20 children and six adults massacred at Sandy Hook Elementary School in Newtown, Connecticut.

Dec 11, 2012

Teva CEO promises to reshape, refocus company by 2017

NEW YORK, Dec 11 (Reuters) – Teva Pharmaceutical Industries’
new Chief Executive Jeremy Levin promised on
Tuesday to reshape the company into “the most indispensable
medicines company in the world” and to provide significant value
to its shareholders along the way.

At a meeting in New York with investors and analysts Levin,
who took over as CEO in May, said Teva would sustain “profitable
growth” through 2017 and beyond despite numerous challenges,
such as the looming 2015 patent expiration of its most important
branded product, the multiple sclerosis drug Copaxone. It
accounts for about 20 percent of Teva sales and an even higher
percentage of its profits.

Dec 8, 2012

Pfizer/Bristol drug cuts recurrence of blood clots – study

By Bill Berkrot

(Reuters) – A new blood clot preventer from Pfizer Inc and Bristol-Myers Squibb Co reduced the risk of recurrence of clots in veins and lungs and death by 80 percent with no increase in major bleeding in a study testing extended use of the drug.

In the year-long trial of 2,486 patients who had been previously treated for the condition known as venous thromboembolism (VTE) the drug, apixaban, met the combined primary goal by significantly reducing the recurrence of blood clots and death from any cause compared with a placebo, according to data presented at the American Society of Hematology (ASH) meeting in Atlanta, Georgia.

Dec 5, 2012

With Teva at crossroads, new CEO set to unveil vision

NEW YORK/TEL AVIV (Reuters) – Teva Pharmaceutical Industries’ new Chief Executive Jeremy Levin has promised investors it will be a very different company going forward. Next week he has to prove it.

Levin’s ability to paint a bright future for the world’s biggest maker of generic drugs at a meeting with investors and analysts on December 11 in New York became a bit more difficult last week, when Teva issued a 2013 earnings forecast that fell short of Wall Street estimates.

Nov 27, 2012

Acadia antipsychotic for Parkinson’s succeeds in trial

Nov 27 (Reuters) – An antipsychotic drug for Parkinson’s
disease patients being developed by Acadia Pharmaceuticals Inc
succeeded in meeting the primary goal and key secondary
goals of a pivotal late stage clinical trial, the company said
on Tuesday.

Acadia shares more than doubled after the company released
initial, or top line, results from the 199-patient Phase III
trial of pimavanserin that showed the drug was significantly
better than placebo at reducing psychotic effects of Parkinson’s
disease psychosis.

Nov 20, 2012

Pfizer, Bristol get EU nod for blood clot preventer

Nov 20 (Reuters) – European health regulators on Tuesday
approved an eagerly anticipated blood thinner developed by
Bristol-Myers Squibb Co and Pfizer Inc for the
prevention of strokes and blood clots in patients who have an
irregular heartbeat known as atrial fibrillation, the companies
said.

The drug Eliquis, also known as apixaban, is widely
considered one of the most important new products for the two
U.S. drugmakers, with multibillion-dollar annual sales
potential.

Nov 14, 2012

Congress takes aim at FDA over meningitis outbreak

WASHINGTON/NEW YORK (Reuters) – Members of a congressional committee investigating the deadly meningitis outbreak on Wednesday accused the Food and Drug Administration of failing to prevent the crisis by moving too slowly against a Massachusetts pharmacy.

Tainted steroids from the pharmacy have so far killed 32 people and sickened 438 people in 19 states, according to the U.S. Centers for Disease Control and Prevention. That number is expected to rise with as many as 14,000 people having been exposed to the drugs injected to ease back pain.

Nov 7, 2012

Novartis heart failure drug cuts death by 37 percent: study

LOS ANGELES (Reuters) – An experimental Novartis AG drug to treat hospitalized acute heart failure patients reduced deaths by 37 percent compared with a placebo and appeared to be safe, according to data from a late stage clinical trial presented on Tuesday.

The drug, serelaxin, which is a form of a human hormone that relaxes blood vessels and eases stress on the heart and other organs, is considered one of the most important medicines in the Swiss drugmaker’s developmental pipeline.

    • About Bill

      "Based in New York, I primarily cover the pharmaceutical and biotechnology sectors as well as other publicly traded companies involved in health care. Previously covered a wide range of sports for Reuters."
    • Follow Bill